

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5404278

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SHINICHI TAIRA	02/27/2019
RECEIVING PARTY DATA		
Name:	OTSUKA PHARMACEUTICAL CO., LTD.	
Street Address:	9, KANDA-TSUKASACHO 2-CHOME, CHIYODA-KU	
City:	TOKYO	
State/Country:	JAPAN	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	11659005	
Application Number:	12970690	
Application Number:	13688108	
Application Number:	14089504	
Application Number:	14928972	
Application Number:	15697196	
CORRESPONDENCE DATA		
Fax Number:	(202)408-4400	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2024084000	
Email:	FAXSERVE@FINNEGAN.COM	
Correspondent Name:	FINNEGAN, HENDERSON	
Address Line 1:	901 NEW YORK AVENUE, NW	
Address Line 4:	WASHINGTON, D.C. 20001-4413	
ATTORNEY DOCKET NUMBER:	01197.0291	
NAME OF SUBMITTER:	AMANDA K. MURPHY	
SIGNATURE:	/Amanda K. Murphy/	
DATE SIGNED:	03/05/2019	
Total Attachments: 2		
source=011970291TairaAssign#page1.tif		

ASSIGNMENT

WHEREAS I/We are the below-named inventor(s) (hereinafter referred to as Assignor(s)) of an invention entitled:

PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS;

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date	Issue Date	Patent Number
2005-116698	JP	April 14, 2005	n/a	n/a
PCT/JP2006/308162	PCT	April 12, 2006	n/a	n/a
11/659,005	US	December 4, 2008	February 15, 2011	7,888,362
12/970,690	US	December 16, 2010	January 8, 2013	8,349,840
13/688,108	US	November 28, 2012	December 31, 2013	8,618,109
14/089,504	US	November 25, 2013	December 8, 2015	9,206,167
14/928,972	US	October 30, 2015	November 1, 2016	9,480,666
15/697,196	US	September 6, 2017	December 12, 2017	9,839,637

WHEREAS, Otsuka Pharmaceutical Co., Ltd., a corporation of Japan whose post office address is 9, Kanda-Tsukasacho 2-chome, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as Assignee), desires to own the entire right, title, and interest in and to this invention in the United States, any and all application(s) for United States Patent(s) filed on this invention, and any and all Letters Patent to be issued upon such filed application(s);

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, interest in and to this invention in the United States, any and all application(s) for United States Patent(s) filed on this invention, including any provisional applications, non-provisional applications, continuations, divisionals, or continuations-in-part that disclose the invention, and any and all Letters Patent to be issued upon such filed application(s), including any reissues thereof;

AND, I/WE covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment.

AND, I/WE authorize and request a patent practitioner of record in this application, to insert the filing date, country of filing, and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

ASSIGNOR (Inventor)

Shinichi Taira

Signature

Shinichi TAIRA

Print Name

Page 1 of 2

Feb. 27, 2019
Execution Date